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Objective: The current study aims at fabrication of an oral bilayer matrix tablet of bosentan monohydrate and sildenafil citrate; the optimisation of 
their in vitro release and characterization, thereby reducing the side effects associated with bosentan, reducing dosing frequency and increasing 
patient compliance in the management of pulmonary arterial hypertension. 
Methods: Methocel K4M Premium DC2, a directly compressible HPMC grade was used as the sustained release polymer. Pregelatinised starch is 
used as a diluent and release modifier and sodium lauryl sulphate (SLS) as a solubiliser. The blends of both layers were prepared, evaluated for 
precompression characteristics and compressed by direct compression. The compressed bilayer tablets were evaluated for their hardness, weight 
variation, friability, content uniformity and swelling index. The principle objective was to assess the influence of the above variables on in vitro drug 
release of Bosentan using a 23
Results: HPMC and pregelatinized starch form a synergistic gel thereby controlling drug release of bosentan for a 12 hour period. Batch BS09 
consisting of 40 mg HPMC, 30 mg Pregeletinized starch and 5 mg SLS showed adequate controlled release for a 12 h period. Immediate release layer 
of sildenafil citrate showed optimum drug release of 102.96% within 30 min. 
 factorial design. Responses are measured as drug release at 2h (Q2), 6h (Q6) and 10h (Q10). 
Conclusion: Bilayer tablet of bosentan and sildenafil is an ideal combination for patients failing monotherapy in pulmonary arterial hypertension. 
Keywords: Bilayer tablet, Bosentan monohydrate, Sildenafil citrate, HPMCK4M DC2Premium, Preletinized starch, SLS, Design expert 




Pulmonary arterial hypertension (PAH) is a rare disease in which 
remodelling of the pulmonary vasculature progressively leads to 
increased pulmonary vascular resistance, right ventricular failure. 
PAH is a specific type of pulmonary hypertension that is caused by 
the development of scar tissue in the tiny blood vessels of the lung. 
This scar tissue blocks the blood flow through the lungs and causes 
the pressure in those blood vessels to increase [1]. 
The dual endothelin receptor antagonist, bosentan, is an orally 
active therapy, which is effective in the treatment of pulmonary 
arterial hypertension the most significant adverse event in patients 
on bosentan treatment is the potential development of abnormal 
hepatic function and specifically a rise in hepatic amino 
transaminases [2]. It has an oral bioavailability of 50% and plasma 
elimination half-life of 5 h [3]. Administration of bosentan as a 
controlled release formulation due to the short half-life would be 
desirable in maintaining the plasma therapeutic levels and thereby 
reducing adverse effects. 
Sildenafil is an orally active, potent and selective inhibitor of 
phosphodiesterase type 5 (PDE5) present throughout the body and 
is found in high concentrations in the lungs [4]. Inhibition of PDE5 
enhances the vasodilator effects of nitric oxide in pulmonary 
hypertension by preventing the degradation of cyclic guanosine 
monophosphate (cGMP), which promotes relaxation of vascular 
smooth muscle and increases blood flow. Sildenafil has been found 
to produce a relatively selective reduction in pulmonary artery 
pressure without adverse systemic hemodynamic effects [5]. 
Pulmonary arterial hypertension is a disease with complex 
pathogenesis, for which combination therapy is an attractive option. 
Studies have assessed the impact of sequential combination therapy 
of bosentan and sildenafil on both short-term responses and long-
term outcomes in patients failing on monotherapy [6]. 
The multi-layered tablet concept has been utilized to develop 
sustained release formulations and co-administers two drugs as a 
fixed dose combination [7]. The present study aims to combine the 
two drugs bosentan and sildenafil for the treatment of pulmonary 
arterial hypertension as a bilayer tablet. The combination therapy 
would help to lower pulmonary hypertension by different mechanisms 
of action in patients failing monotherapy, thereby reducing frequency 
of dose, side effects and thus improving patient compliance. The 
objective was to formulate a bilayer tablet wherein bosentan is 
sustained release and sildenafil is the immediate release layer. 
Methocel K4M Premium DC2, a directly compressible hydroxypropyl 
methylcellulose (HPMC) grade has been used as the sustained release 
polymer. Pregelatinized starch is used as a diluent and release 
modifier and sodium lauryl sulphate (SLS) as a solubiliser. The further 
objective was to assess the influence of the above variables on drug 
release of bosentan. This was accomplished using the statistical design 
of experiments using the Design expert software, trial version 11. 
MATERIALS AND METHODS 
Bosentan monohydrate was gifted by Cipla Ltd. Goa, sildenafil citrate 
was gifted by Unichem Laboratories Pvt. Ltd. Methocel K4M 
Premium DC was gifted by Colorcon Asia Pvt. Ltd. Goa; 
pregelatinized starch byIndocco Remeides Pvt. Ltd. Goa; MCC pH 
102 and other excipients from Arihant chemicals, Mumbai. 
Formulation of sildenafil citrate immediate release blend 
The dose of sildenafil which is the immediate release layer is 20 mg. 
22.47 mg of sildenafil citrate equivalent to sildenafil is weighed. The 
blend for immediate release layer as given in table 1was prepared by 
mixing the drug with super disintegrant in the mortar and pestle, 
following which other ingredients were blended into, mixed for 15 
min and sieved through sieve no# 80. The tablets of sildenafil were 
compressed using Rimek Mini Press II MT (Karnavati Engineering 
Private Ltd.). Final weight of the tablet was 130 mg [8]. 
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Table 1: Formulation of sildenafil citrate blends 
Ingredients (mg/tab) Formulations 
SC01 SC02 SC03 SC04 
Sildenafil citrate 22.47 22.47 22.47 22.47 
Crosscarmellose sodium 5 10 --- ---- 
Crosspovidone --- ---- 5 10 
Calcium Hydrogen Phosphate anhydrous 40 40 40 40 
MCC Ph102 61 61 61 61 
Magnesium stearate 1 1 1 1 
Aerosil 0.53 0.53 0.53 0.53 
Total tablet weight (mg) 130 135 130 135 
MCC: Microcrystalline Cellulose 
 
Formulation of bosentan monohydrate sustained release component using 23
Various preformulation trials were carried out for selection of matrix polymer to sustain the release of bosentan. Methocel K4M PemiumDC2 was 
found to show promising sustained release effect for desired period of time. The sustained release layer was formulated with the drug, Methocel 
K4M PemiumDC2, pregelatinized starch as a diluent and release modifier and sodium lauryl sulfate (SLS) as a solubilizer. The effect of each key 
ingredient was studied using a 2
 factorial design 
3
 
 factorial design containing 3 factors at 2 levels and center point batches repeated four times to assess the 
experimental error of the model. The dependent response variables measured were the percentage of bosentan release at 2, 6 and 10h. Table 2 
shows the variables and their concentrations according to the design expert software trial version 11.  




X X1 X2 3 
Concentration of methocel K4M premium DC2 
per tablet (mg) 
Concentration of pregelatinized starch 
per tablet (mg) 
Concentration of SLS per 
tablet (mg) 
-1 30 20 0 
+1 50 40 10 
 
A total of twelve batches were compressed (table 3), of which eight 
batches-BS01-BS08, comprised of a varying concentration of 
independent variables and BS09-BS12 were the four repeated center 
point batches. The blend of sustained release was prepared by 
mixing drug with Methocel K4M premium DC2 and SLS in a 
laboratory blender for 15 min. The rest of the ingredients were 
blended into for the next 10 min. Finally, magnesium stearate was 
added and blended. The tablets were compressed using Rimek Mini 
Press II MT of Karnavati Engineering Private Ltd. The final weight of 
the sustained release component was 170 mg. 
Both the immediate and sustained release blends were evaluated for 
precompression parameters such as bulk density, tapped density, 
angle of repose and carr’s compressibility index [9, 10]. 
 
Table 3: Formulation blends of bosentan monohydrate layer 
 Composition BS01 BS02 BS03 BS04 BS05 BS06 BS07 BS08 BS09 BS010 BS11 BS12 
Bosentan monohydrate 64.54 64.54 64.54 64.54 64.54 64.54 64.54 64.54 64.54 64.54 64.54 64.54 
HPMC K4M DC 30 50 30 50 30 50 30 50 40 40 40 40 
Pregelatinized starch 20 20 40 40 20 20 40 40 30 30 30 30 
SLS 0 0 0 0 10 10 10 10 5 5 5 5 
sunset yellow FCF 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 
magnesium stearate 2 2 2 2 2 2 2 2 2 2 2 2 
MCC ph102 (qs) 53 33 33 13 43 23 23 3 28 28 28 28 
Total weight (mg) 170 170 170 170 170 170 170 170 170 170 170 170 
 
Formulation of bilayered tablet of bosentan monohydrate and 
sildenafil citrate 
The twelve blends of bosentan monohydrate were compressed with 
the optimised sildenafil blend SC01 using tablet compression machine 
(Rimek Mini Press II MT (Karnavati Engineering Private Ltd) and were 
further evaluated. The bilayer tablet was prepared by adding the 
sustained release blend of bosentan into the die cavity and 
compressing lightly followed by compressing the immediate release 
blend of sildenafil over it thereby obtaining the bilayer tablet [11]. 
Evaluation 
The bilayered tablet was evaluated for physical tests like hardness 
(Monsanto hardness tester-Pathak Electrical Works), friability (Roche 
friabilator-Pathak Electricals), thickness (Vernier calliper-Bliss 
Classic), drug content, uniformity of weight and swelling index. 
Incompatibilities between drugs and excipients were ruled out by DSC 
and FTIR studies. In vitro disintegration time for sildenafil immediate 
release component was evaluated using USP tablet disintegration 
apparatus with 0.1 N Hcl as medium. The volume of medium used was 
900 ml and the temperature was 37±0.5 °C. The time taken for 
complete disintegration of the IR layer was measured [9-11]. 
In vitro drug release 
The in vitro drug release of bilayered tablet was studied using 
900 ml 0.1 N HCl for the first one hour followed by 11 h in 900 
ml phosphate buffer pH 7.2 using USP type II paddle apparatus 
using at 50 rpm at 37±0.5 °C. The samples were withdrawn 
every one hour for a period of 12 h and replaced with the fresh 
buffer. The samples were analysed using double beam UV-Visible 
spectrophotometer at 271 nm and 290 nm for bosentan and 
sildenafil respectively [12].  
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The tablets were weighed (W0) and placed in a petridish containing 
buffer and incubated at 37±1 °C. At regular time intervals until 12 h, 
the tablet was removed carefully and the excess buffer was removed 
with blotting paper. The swollen tablet was then reweighed (Wt) 
and the percent swelling was calculated as follows:  
100 × W0)/W0}-{(Wt = swelling %  
Where Wt is the weight of tablet at time t and W0 is the initial 
weight of tablet. The swelling index was calculated [13]. 
Statistical analysis 
Statistical analysis was done using Design Expert® 11 software. 
The responses analysed were the drug release Q2 (at 2 h), Q6 (at 
6 h) and Q10 (10 h). The effect of independent variables on 
response was represented through contour plots and response 
surface plots. Significance of results was studied through two-
way analysis of variance (ANOVA) wherein P<0.05 was 
considered significant [13-14]. 
Drug release kinetics 
Kinetics of drug release was studied by analysing the dissolution 
data through zero order, first order, Higuchi’s and Korsmeyer 
Peppas equations [15]. 
Accelerated stability study  
The optimized batch was subjected to stability study as per ICH 
guidelines [16].  
RESULTS AND DISCUSSION 
The results of precompression characteristic have been tabulated in 
table 4 and 5 for immediate release and sustained release blend 
respectively. Bulk and tapped densities indicate good packing properties. 
The carr’s index for all formulations was below 17.3% indicating good 
flow and compressibility. The angle of repose for all blends lies between 
the ranges of 12.64 °-22.75 ° further ascertaining good flow. 
The compressed tablets were evaluated for their hardness, weight 
variation, friability, content uniformity, and diameter. As shown in 
table 6, all the parameters were found to be within range. 
 
Table 4: Precompression characteristics of sildenafil citrate blends 
Formulation code Angle of reposea Bulk density (g/ml)° Tapped density a a Carrs Index (g/ml) a(%) 
SC01 21.84±0.57 0.43±0.03 0.51±0.03 15.68 
SC02 21.37±0.19 0.43±0.04 0.52±0.08 17.30 
SC03 22.49±0.42 0.42±0.05 0.50±0.07 16 
SC04 22.75±0.38 0.40±0.03 0.48±0.05 16.66 
a
 
mean±SD, n = 3 
Table 5: Precompression characteristics of bosentan monohydrate blends 
Formulation code Angle of repose Bulk densitya a Tapped density  (g/ml) a Carrs index (%) (g/ml) 
BS01 21.57±0.62 0.41±0.08 0.46±0.04 10.86 
BS02 20.14±0.22 0.42±0.05 0.48±0.11 12.5 
BS03 18.54±0.87 0.43±0.07 0.49±0.09 12.22 
BS04 19.31±1.0 0.38±0.1 0.42±0.08 9.52 
BS05 18.54±0.32 0.36±0.08 0.41±0.06 12.19 
BS06 16.66±0.54 0.35±0.04 0.42±0.05 16.66 
BS07 15.41±0.87 0.36±0.09 0.40±0.08 10.0 
BS08 12.64±0.55 0.34±0.08 0.39±0.09 12.8 
BS09-BS12 14.65±0.21 0.33±0.04 0.38±0.24 13.15 
a
 
mean±SD, n = 3 







Weight Variationa Friability  
(mg) (%) 







BS01 8.5±0.23 4 300±0.56 0.29±0.0021 79 99.12±0.67 99.21±0.57 
BS02 10.3±0.35 4 300±0.34 0.41±0.0074 85 99.87±1.07 99.57±0.64 
BS03 9.8±0.87 4 300±0.57 0.51±0.0041 84 100.35±0.44 98.64±1.28 
BS04 10.5±0.47 4 300±0.69 0.38±0.005 90 99.74±0.56 99.24±0.55 
BS05 8.7.0±0.17 4 300±0.46 0.63±0.0087 75 100.67±0.32 98.54±0.97 
BS06 10.1±0.61 4 300±0.49 0.49±0.0097 89 98.62±1.06 99.69±1.64 
BS07 9.5±0.31 4 300±0.78 0.55±0.0035 88 99.79±1.13 98.82±1.47 
BS08 11.0±0.45 4 300±0.81 0.17±0.0047 100 100.54±0.64 99.16±0.57 





mean±SD, n = 3 
The thermograph of pure drug bosentan monohydrate showed 
the melting point to be 197.94 °C and of sildenafil citrate 187.30 
°C, which is as reported in the literature. The thermographs of 
the mixture of both drugs, as well as drug and excipient 
mixtures,  does not reveal a significant change in the melting 
points of bosentan and sildenafil, thus ruling out in-
compatibilities as depicted in fig. 1. 
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Fig. 1: Compatibility studies of drugs and excipients using DSC 
 
In vitro drug release 
From the four batches of sildenafil citrate, SC01 containing 
croscarmellose sodium as disintegrant showed optimum drug 
release of 102.96% within 30 min. Hence this blend was further 
selected to be compressed against the 12 batches of bosentan 
monohydrate sustained release blends. 
 
 
Fig. 2: Cumulative drug release profiles of sildenafil citrate immediate release component (mean±SD, n = 3) 
 
The release of sustained release bosentan monohydrate from the 
12 batches of bilayer tablets is as given in fig. 3. All batches 
showed drug release varying from 8-12 h depending on the 
concentration of independent variables. Batches BS01-BS04 that 
do not contain solubiliser SLS do not show complete drug release 
at the end of 12 h. This may be attributed to the saturation of the 
drug released in the dissolution vessel after 5-6 h. Formulations 
BS05-BS09 containing SLS as solubilizer showed adequate drug 
release. Formulations BS05 and BS07 containing 30 mg of HPMC 
K4M DC2 Premium per tablet could control the release for 8-9 h, 
whereas formulations BS06 and BS08 containing 50 mg HPMC 
showed adequate control for a 12 h period as desired. 
Pregelatinized starch was observed to have a synergistic effect 
along with HPMC on controlling the drug release. Formulations 
BS09 which was the center point batch containing 40 mg HPMC, 30 
mg pregelatinized starch and 5 mg SLS per tablet was observed to 
be the best-optimised formulation. The dissolution profile of the 
optimised bilayer tablet is depicted in fig. 4. 
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Fig. 3: Cumulative drug release profiles of bosentan monohydrate sustained release component (mean±SD, n = 3) 
 
 
Fig. 4: Dissolution profile of optimised batch of bilayer tablet (mean±SD, n = 3) 
 
To describe the entire dissolution profile, three-time points were 
considered in the design expert software. Fig. 5 shows the 
response surface plot for drug release at 2 h (Q2). As depicted, as 
the concentration of HPMC increases from 30 mg to 50 mg per 
tablet, the percent drug released is controlled. The same 
phenomenon is observed with pregelatinized starch as well, but 
to a lesser extent than HPMC. SLS does not have a significant 
effect at 2 h. 
  
 
Fig. 5: Response surface plot for drug release at 2 h (Q2) (n=3) 
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At 6 h and 10 h, HPMC continues to show a dominant effect on 
controlling the drug release along with pregelatinized starch. This is 
attributed to the formation of swollen gel of HPMC. HPMC along with 
pregelatinized starch forms a synergistic matrix gel thereby 
influentially controlling the drug release for 12 h period. The influence 
of pregelatinized starch is most dominant at 6 h. A very significant 
influence of SLS was observed at 6 h and 10 h. As depicted in fig. 6 and 
7 it was observed that as SLS concentration increases from 0 to 10 mg 
per tablet the release of drug increases at 6 h and 10 h. This may be 
attributed to the fact that bosentan being a BCS class II drug, having a 
solubility of around 40 mg/100 ml in phosphate buffer pH 7.2, may 
pose a problem in the drug getting solubilised in the dissolution vessel 
after 6 h. Therefore the addition of SLS as a solubiliser in the tablet 
helps to enhance the solubility of the drug as it is released. 
 
 
Fig. 6: Response surface plot for drug release at 6 h (Q6) (n=3), fig. 6(a) Drug release at 6 h when concentration of SLS is 0, fig. 6(b) Drug 
release at 6 h when concentration of SLS is 5, fig. 6(c) Drug release at 6 h when concentration of SLS is 10 
 
 
Fig. 7 Response surface plot for drug release at 10 h (Q10) (n=3), Fig. 7(a) Drug release at 10 h when concentration of SLS is 0, Fig.7(b) 
Drug release at 10 h when concentration of SLS is 5, Fig. 7(c) Drug release at 10 h when concentration of SLS is 10 
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The statistical data obtained from ANOVA for the models is 
represented in table VII. From the ANOVA analysis, it can be observed 
that HPMC K4M DC2 Premium(X1) polymer has effect on all responses 
Q2, Q6 and Q10reinforcing the fact that it is the main release retarding 
polymer that controls the drug release upto12 h. At two hours the 
coefficient, as observed from the equation in table 7 has a lesser value 
as this is the period of establishment of a fully swollen gel matrix. This 
is also reinforced by the swelling index of the tablet as depicted in fig. 8 
for optimised batch BS09. It was also observed that as the HPMC 
content per tablet increases the swelling index also increases. 
Pregelatinized starch has significant influence at 6 h as observed from 
the equation in table. It forms a synergistic gel matrix with HPMC. The 
influence of SLS as solubilser for drug is most predominant from 6 h 
onwards till 12 h. Since P<0.05 for all three responses, indicates that 
the model is significant. R2values indicate a high level of correlation 
between experimental and predicted responses. The closeness of the 
adjusted and predicted R2
 
 values explains the reliability of the model. 
The adequate precision value of greater than 4 indicates that the 
model is discriminating. Since coefficient of variation CV is less than 10 
the model can be considered reproducible. 
Table 7: ANOVA influence of formulation variables on response factors 










Q2= 13.90-3.05 X1–1.31 X2+0.540 X3 0.9134 0.8810 0.8384 0.0001 7.45 16.3950 
Q6= 51.86–7.83 X1–5.31 X2+9.80 X3+1.71 X1*X2–2.39 
X1*X3 
0.9937 0.9884 0.9730 <0.0001 2.50 50.4568 
Q10 = 80.22–8.52 X1–3.28 X2+9.23 X3–2.45 X1*X3 0.9686 0.9506 0.9096 <0.0001 3.17 25.6130 
 
 
Fig. 8: Swelling index of optimised batch BS09 (mean±SD, n = 3) 
 
The release kinetics of all the formulations were checked by fitting 
the release data to various kinetic models, and the release was best 
fitted to zero order release mechanism. Further by fitting the data to 
the Korsmeyer‑Peppas equation and the n value for all the 
formulations obtained was>1 which suggests that the release 
followed the super case II transport mechanism. This suggests more 
than one mechanism involved in drug release from matrix. The r2
Stability results of the optimised batch BS09 showed optimum drug 
release of sildenafil citrate within 30 min and controlled release of 
bosentan over a 12 h period. 
 
values for all the models are shown in table 8. 
 
Table 8: Correlation coefficients of different pharmacokinetic models for release 
Formulation zero order first order Higuchi Hixon crowel Korsmeyer-peppas r2 n 
BS 01 0.9479 0.9703 0.949 0.972 0.8756 1.6175 
BS 02  0.9872 0.981 0.9299 0.9889 0.8924 1.5739 
BS 03 0.9936 0.969 0.9253 0.9859 0.8634 1.5766 
BS 04 0.9963 0.9542 0.8917 0.9762 0.9289 1.6068 
BS 05 0.8972 0.8722 0.9086 0.8444 0.9148 1.7362 
BS 06 0.9727 0.9809 0.9408 0.9933 0.918 1.6662 
BS 07 0.9669 0.864 0.9251 0.867 0.9093 1.7243 
BS 08 0.9927 0.9556 0.9201 0.9851 0.9383 1.6739 
BS 09 0.9947 0.7802 0.9149 0.9119 0.9267 1.6989 
BS 10 0.9881 0.7819 0.9179 0.9005 0.9129 1.6613 
BS 11 0.997 0.6618 0.9073 0.8632 0.9265 1.7089 
BS 12 0.9925 0.8644 0.9266 0.9498 0.9169 1.6773 
 
CONCLUSION 
The above study demonstrates the use of a factorial design approach in 
an optimisation of bilayer tablet dosage form of bosentan monohydrate 
and sildenafil citrate in the management of pulmonary arterial 
hypertension. The amount of HPMC and amount of pregelatinized starch 
has the significant influence on in vitro drug release. SLS acts as a 
solubilizer exhibiting significant influence after 6 h. The statistical tool 
design expert trial version 11 was used to predict the interaction 
between the variables and the extent of their influence on drug release. 
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The direct compression technique for manufacture of this bilayer tablet 
is a safe and effective tool for patients failing monotherapy in pulmonary 
arterial hypertension. Bilayer tablets are an ideal way of administering 
drugs as fixed dose combinations for lifestyle diseases. 
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